Constitutive activation of IRE1 and PERK and their associated downstream pathways has been reported in multiple cancers including triple negative breast cancer, prostate cancer, lung cancer, and, more recently, sarcomas including RMS (RMS) [355,356,357]. The gene discussed is ERN1; the disease is prostate cancer.